NewsSource: EClinCloud

Livestream Preview | Application and Practice of eCOA in Patient-Centric DCT Clinical Trials

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud.

On July 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) officially issued and implemented three technical guidelines: "Technical Guidelines for Patient-Centered Drug Clinical Trial Design (Trial)," "Technical Guidelines for Patient-Centered Drug Clinical Trial Implementation (Trial)," and "Technical Guidelines for Patient-Centered Drug Benefit-Risk Assessment (Trial)" (hereinafter referred to as the "three consecutive guidelines"). The three consecutive guidelines reiterate the importance of reflecting patient-centricity in clinical trials, incorporating patient experience data into clinical trials, and optimizing patients' clinical trial experience.

Meanwhile, in patient-centric DCT clinical trials, the advantages of using electronic clinical outcome assessment (eCOA)/electronic patient-reported outcome (ePRO) to collect patient data have also gradually become apparent.

The application of eCOA not only helps improve clinical trial efficiency and data quality, but also, under a patient-centric approach, enables more effective patient management and more scientific evaluation of clinical efficacy.

What is eCOA?

From paper to electronic, what is the value of eCOA compared with paper COA?

As source data, can eCOA data be modified?

What is the stance of global regulatory authorities on the use of eCOA?

……

On August 25, 2023, from 19:00 to 20:00, EClinCloud invites you to join the CMAC livestream, where Su Quanyu, Co-Founder and Chief Business Officer of EClinCloud, will share a forward-looking perspective and provide a detailed introduction to the application and practice of eCOA.

“

Industry colleagues are welcome to tune in and join the discussion.

Scan the QR code on the poster below to register for the livestream:

Article illustration




About EClinCloud

EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interconnected all-in-one clinical trial cloud platform (including technology products such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, as well as solutions within these offerings such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) and clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system and ophthalmology). By combining cutting-edge technology with life data, EClinCloud is building a globally leading patient-centric SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration



Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.